CLXT - Calyxt: Proprietary TALEN Plant-Technology Offers Multi-Industry Growth

• Calyxt is a plant-technology company that develops plant-based innovations and solutions aiming to disrupt a broad group of industries.
• Calyxt is a leading gene-editor with exclusive access to the parent company's proprietary TALEN technology for use in plants which resulted in the first successfully US-commercialized gene-edited food product.
• Calyxt's pipeline of clinical-stage gene-edited plant products includes improved digestibility alfalfa (Phase 3), high fiber wheat (Phase 3), and high oleic low linolenic soybeans (Phase 2/program stopped until 2022), among others.
• Calyxt is struggling financially with $20.4M in cash as of March 31, 2021, with a runway into 2H 2022, as outlined by the company guidance alongside historical 2020 revenues reaching $23.9M with a net loss of -$45M.
• In summary, the author projects Calyxt, Inc. as a "buy" at a 2-3 year Wall Street price target of $7.17/share (+74% upside).

For further details see: